Strides Pharma Science Ltd. exhibits moderate growth and profitability compared to its peers, but its high valuation metrics suggest it may be overvalued. While it maintains a relatively strong debt level, its overall performance is overshadowed by companies with stronger financial metrics and lower valuations, positioning Strides as a potential sector laggard in terms of growth and profitability.

• • Strides Pharma shows moderate revenue growth (YoY) at 9.83%, lower than several peers.
• • High PE ratio of 138.44 signals potential overvaluation compared to earnings.
• • EPS growth is positive, but not competitive against peers like Cipla and Dr. Reddy's.
• • Debt levels are manageable but not the lowest in the sector.